A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM

Inclusion Criteria: * Patients with type 1 diabetes presenting with any of the following conditions: Impaired hypoglycemia awareness (lack of sufficient autonomic symptoms when plasma glucose is below 54 mg/dL \[3 mmol/L\]) or other clinically diagnosed neuropathy caused by type 1 diabetes, including but not limited to gastrointestinal autonomic neuropathy Metabolic instability: two or more previous severe hypoglycemic events that required assistance from others, or two or more hospitalizations for ketoacidosis in the past year * Age ≤ 60 years * Body weight ≥ 40 kg * At least one positive islet autoantibody, including glutamic acid decarboxylase autoantibody (GADA), protein tyrosine phosphatase autoantibody (IA-2A), insulin autoantibody (IAA) (only applicable within 2 weeks of insulin treatment), zinc transporter 8 antibody (ZnT8), islet cell autoantibody (ICA), etc. * MMTT stimulated C-peptide peak \> 0.1 nmol/L, or fasting C-peptide \> 0.05 nmol/L * Female subjects of childbearing potential must have a negative serum or urine pregnancy test at screening * Both male and female subjects must be willing to use contraception from the time of signing the informed consent form until 12 months after cell infusion * The subject or their legal guardian voluntarily participates in this study and is able to sign the informed consent form Exclusion Criteria: * If any of the following criteria are met, the subject will be excluded from the study. Type 2 diabetes, or diabetes mell…